title: [Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic].
abstract: BACKGROUND
  Oral anticoagulants are broadly used in cardiology. However, it is still necessary to evaluate their use in clinical practice.
  
  
  OBJECTIVE
  To describe the differences in the maintenance of anticoagulation control, as well as the incidence of hemorrhagic and thromboembolic events among users of warfarin and phenprocoumon.
  
  
  METHODS
  Non-concurrent cohort study of 127 patients using oral anticoagulation.
  
  
  RESULTS
  Phenprocoumon was the most frequently used anticoagulant in 60% of the patients. The prevalence of RNI<2 at the last medical appointment was higher among warfarin users (46% vs. 19.5%; p<0.001). During the follow-up, Phenprocoumon users were within the therapeutic range during 60.7% of the period, in comparison with 45.6% of warfarin users (OR:1.84; 95%CI:1.59-2.13; P<0.001). The incidence of bleeding was 5.3/100 patients/year in the phenprocoumon group versus 18.8/100 patients/year in the warfarin group (RR: 3.5; 95%CI: 1.87-6.48; P<0.001).
  
  
  CONCLUSIONS
  Patients that used Warfarin remained at subtherapeutic levels for a longer period; however, they also presented more hemorrhagic events. Phenprocoumon users were younger and had been using oral anticoagulation for longer periods, presenting fewer drug-related adverse events.
authors.affiliation: Instituto de Cardiologia do Rio Grande do Sul, FUC, Porto Alegre, RS, Brasil.
authors.forename: Tiago Luiz Luz
authors.initials: TL
authors.lastname: Leiria
authors.forename: Lucia
authors.initials: L
authors.lastname: Pellanda
authors.forename: Marcelo Haertel
authors.initials: MH
authors.lastname: Miglioranza
authors.forename: Roberto Tofani
authors.initials: RT
authors.lastname: Sant'anna
authors.forename: Lucas S
authors.initials: LS
authors.lastname: Becker
authors.forename: Eros
authors.initials: E
authors.lastname: Magalhães
authors.forename: Gustavo Glotz de
authors.initials: GG
authors.lastname: Lima
mesh_terms: D000284:Administration, Oral; D000554:Ambulatory Care Facilities; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001938:Brazil / Q000453:epidemiology; D004812:Epidemiologic Methods; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000009:adverse effects* / Q000627:therapeutic use; D011516:Prothrombin / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D011516:Prothrombin; D010644:Phenprocoumon